For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was ...

A study published inClinical Cancer Research found that in patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and immunotherapy made ...

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...

SAN FRANCISCO -- Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab significantly increased pathological complete response (pCR) rates compared with ...

A new cervical cancer treatment is showing promise in boosting survival rates and reducing recurrence What this breakthrough means for patients.

The analysis also did not identify any pathologic or demographic factors predictive of a survival benefit in the chemoradiotherapy arm. The study, led by Daniela E. Matei, MD, Northwestern ...

Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 5.40 Gy. The primary end point was overall survival. The results of this study were ...

For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with FLOT leads to improved survival compared with preoperative chemoradiotherapy.

GOBLET study: Results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +/- atezolizumab. This is an ASCO ...

For advanced gastric cancer, randomised studies have emphasised the importance of combining chemotherapy or chemoradiotherapy with surgery as a strategy to improve outcomes beyond surgery alone.1 ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab ...